Andere talen Purple Biotech Ltd

Aandelen

PPBT

IL0007650166

Beurs gesloten - TEL AVIV STOCK EXCHANGE Andere beurzen 14:49:49 12-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
19,4 ^ILa	-2,51%		-7,18%	-39,18%

25/04	Purple Biotech Ltd.'s gerandomiseerde Fase 2 CM24-studie naar alvleesklierkanker geselecteerd als late presentatie van het Abstract op de jaarlijkse ASCO 2024-bijeenkomst	CI
14/03	Purple Biotech rapporteert preklinisch proof of concept voor zijn Tribody-platformtechnologie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	25/04
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	28/03
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	14/03
Purple Biotech : Immediate Report	06/03
6K:Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	27/02
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	27/02
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	13/02
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	01/02
Purple Biotech Ltd. Announces Executive Changes	20/12
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	30/11
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11
Purple Biotech Reports Third Quarter 2023 Financial Results	21/11
Purple Biotech Fortifies NT219 Patent Protection	02/11
Purple Biotech : Other Report or Announcement	31-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Purple Biotech Ltd

Aandelen

PPBT

IL0007650166

Andere talen

Filters